Drug research

ANX005

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)NCT04569435	ANNX	Phase 2	Completed	2024-01-10Actual
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré SyndromeNCT04701164	ANNX	Phase 3	Completed	2024-04-20Actual
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)NCT04691570	ANNX	Phase 2	Completed	2023-01-17Actual
An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's DiseaseNCT04514367	ANNX	Phase 2	Completed	2022-08-29Actual

ANNXCompletedPrimary completion: 2024-01-10 · Actual

Trial details

ANNXCompletedPrimary completion: 2024-04-20 · Actual

Trial details

ANNXCompletedPrimary completion: 2023-01-17 · Actual

Trial details

ANNXCompletedPrimary completion: 2022-08-29 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.